There were 1,641 press releases posted in the last 24 hours and 442,761 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Arvinas Announces Updated Phase 1 Data Demonstrating Clinical Activity of PROTAC® Protein Degrader ARV-110 in Patients with Refractory Prostate Cancer

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image